In another phase I trial of the MDM2 inhibitor alrizomadlin, conducted in patients predominantly diagnosed with advanced liposarcoma who had progressed on standard therapy, a partial response was achieved in 2 patients, while 10 patients experienced stable disease [26]. Here, MDM2 is linked to liposarcoma.